Mustafa Ilteris Bardakçı

Dr. Mustafa Ilteris Bardakçı

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
MBMustafa Ilteris Bardakçı
Mustafa Ilteris Bardakçı
EOEsin Nagihan Ozturk
Esin Nagihan Ozturk
MÖMüfide Arzu Özkarafakılı
Müfide Arzu Özkarafakılı
HOHuseyin Ozkurt
Huseyin Ozkurt
UYUgur Yanc
Ugur Yanc
DSDilek Yildiz Sevgi
Dilek Yildiz Sevgi
Objective: It was aimed to evaluate long‐term radiological changes in severe coronavirus disease 2019 (COVID‐19) patients, to investigate pulmonary function, exercise capacities, and health‐related quality of life results.Methods: Sixty‐five patients with severe COVID‐19 pneumonia were evaluated in the sixth month after discharge from the hospital. Spirometry, 6 min walking test (6MWT), and short form of health‐related quality of life scale (SF‐36) were applied in the sixth month. Chest computed tomography (CT) was performed and the findings were grouped according to lung involvement.Results: Forty‐nine male and 16 female patients were included in the study. Forced expiratory volume in 1 s (FEV1)% values of 18 patients (30.5%), forced vital capacity (FVC)% values of 27 patients (45.8%), and 6MWT of 13 patients (23.2%) were found lower than expected in the sixth month. On the SF‐36 scale, physical function, energy‐vitality, social functionality, pain, and general health parameters were found lower than normal. Minimal interstitial changes in chest CT were seen in 26 patients. Nine patients had lung area involvement between 10% and 50% of the surface, there was a correlation between FEV1% and FVC% values in this group. There was severe pulmonary fibrosis in four patients. There was a correlation between pulmonary function and physical function and general perception of health from SF‐36 scale subparameters.Conclusion: Functional and radiological abnormalities were detected in a significant number of patients in the sixth month after severe COVID‐19 pneumonia. A systematic monitoring plan must be established to assess and properly manage the long‐term problems that may arise.

30 April 2024 in Journal of Medicine and Palliative Care
Verified
Journal Article
Open access
PDF file
GAGülhan Albayrak
Gülhan Albayrak
MBMustafa Ilteris Bardakçı
Mustafa Ilteris Bardakçı
MÖMüfide Arzu Özkarafakılı
Müfide Arzu Özkarafakılı
Aims: Postoperative pulmonary complications (PPC) that may develop after surgery are important causes of morbidity and mortality. PPCs cause a prolongation of hospital stays and an increase in hospitalization costs. The study aims to determine factors associated with PPCs to predict PPCs in surgical patients undergoing preoperative evaluation. Methods: A retrospective cohort study was conducted at Şişli Hamidiye Etfal Training and Research Hospital using data from 200 patients referred for preoperative pulmonary evaluation from anesthesia and surgery clinics. This study analyzed the characteristics and outcomes of patients with PPC and those without PPC. The Canet pulmonary risk scores are used for PPC in all preoperative surgery patients. The study’s primary endpoints are to determine the development of respiratory failure, bronchospasm/asthma, COPD exacerbation, atelectasis, pleural effusion, or pneumonia. The study also analyzed the effective respiratory function parameters for PPC development using a logistic regression model. Results: The total study population included 200 patients with a median age of 53.5 years (aged between 19-88), 103 (51.5%) of whom were female. PPCs were observed in 38% (n=76) of the study group. There was a statistically significant difference between the patients in terms of the development of postoperative pulmonary complications according to gender (higher in males, p=0.001) and smoking (p=0.0001). Preoperative oxygen saturation (SpO2) and FEV1/FVC ratio were significant predictors of PPC development, and complications were more frequent in low-saturated patients (p=0.0001, p=0.013 respectively). The relationship between SpO2 and PPC was confirmed via logistic regression analysis. A one-unit increase in saturation reduced the occurrence of postoperative respiratory complications by 0.645-fold. The cut-off value for the saturation value was 97.5%, with a sensitivity of 46.8% and a specificity of 71.1% [p=0.0001, 95% CI, (0.521-0.798)]. Conclusion: In this study, the Canet (ARISCAT) score, a preoperative evaluation scale validated in Turkey that predicts postoperative pulmonary complications and mortality, was used. The Canet risk score is a simple risk score with moderate discriminatory performance for predicting PPCs. It may be useful in identifying individual patients at high risk of PPC and in the design of future studies to evaluate interventions to prevent these complications. However, a customized preoperative risk assessment system is needed for each patient.

31 August 2023 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
MBMustafa Ilteris Bardakçı
Mustafa Ilteris Bardakçı
EOEsin Nagihan Ozturk
Esin Nagihan Ozturk
MOMüfide Arzu Ozkarafakili
Müfide Arzu Ozkarafakili
HOHüseyin Ozkurt
Hüseyin Ozkurt
UYUğur Yanc
Uğur Yanc
DYDilek Sevgi Yıldız
Dilek Sevgi Yıldız
Introduction: We aimed to investigate the effects of COVID-19 on patients 24 months after severe COVID-19 pneumonia. Methodology: Fifty-four patients with severe COVID-19 pneumonia were evaluated on the 24th month after discharge from the hospital. Spirometry and short form of health-related quality of life scale (SF-36) were used. Chest computed tomography (chest-CT) was performed and the findings were grouped according to lung involvement. Results: Forced expiratory volume in 1 second (FEV1) % values of 19 patients (35.18%) and forced vital capacity (FVC) % values of 23 patients (42.54%) were found lower than expected on the 24th month. Physical function, energy-vitality, social functionality and general health parameters were found lower than normal on the SF-36 scale. 27 (50.00%) patients had a chest-CT abnormality. There was a correlation between FEV1% and FVC% values and group 3: medium-lower lobe dominant, reticulation + traction, 10-50% surface area. Chest-CT of 6 patients was fully recovered. No correlation was found between chest-CT findings on the 24th month and BMI, length of hospitalization, white blood cell (WBC), lymphocyte, C-reactive protein (CRP), ferritin and D-dimer values at the time of hospitalization. Conclusions: Functional and radiological abnormalities were detected in a significant number of patients on the 24th month. A systematic monitoring plan must be established to assess and properly manage the long-term problems that may arise.

17 June 2022 in Bagcilar Medical Bulletin
Verified
Journal Article
Closed access
MÖMüfide Arzu Özkarafakılı
Müfide Arzu Özkarafakılı
ZYZeynep Mine Yalçınkaya
Zeynep Mine Yalçınkaya
MBMustafa Ilteris Bardakçı
Mustafa Ilteris Bardakçı
IAIsil Kibar Akilli
Isil Kibar Akilli

7 January 2026 in Canadian Respiratory Journal
Verified
Journal Article
Open access
GAGulhan Ayhan Albayrak
Gulhan Ayhan Albayrak
MBMustafa Ilteris Bardakçı
Mustafa Ilteris Bardakçı
UTUgur Temel
Ugur Temel
Objective: Pulmonary fibrosis may develop in patients with severe clinical conditions, especially those with high inflammatory indicators. We aimed to investigate the 15‐month follow‐up clinical outcomes in patients with moderate‐to‐severe COVID‐19 pneumonia treated with colchicine and to evaluate its potential in preventing post‐COVID pulmonary fibrosis. Method: This study, beginning with a retrospective analysis of 1489 selected patients, and a follow‐up assessment of 155 patients conducted 15 months after hospital discharge. This study included 90 patients presenting with COVID‐19 pneumonia with severity ranging from moderate to severe who were treated with colchicine alongside standard care, and 65 patients who did not receive colchicine were included in the control group to serve as a comparator. Patients who received colchicine treatment were included in Group 1, and those that did not in Group 2. Results: From admission to the 15‐month follow‐up, patients receiving colchicine exhibited a significant regression in chest CT abnormalities when compared with the control group ( p < 0.05). Additionally, 65.6% ( n = 59) of the colchicine group experienced symptomatic improvement, significantly higher than 35.4% ( n = 23) in the control group ( p < 0.05). Ninety patients who received colchicine treatment had Stage 3, 4, or 5, and only 28 had Stage 3, 4, or 5 pulmonary fıbrosis at the end of 15 months. After 15 months of follow‐up, all 20 patients initially classified as Stage 5 who received colchicine remained at Stage 5 pulmonary fibrosis, whereas in the control group, 2 patients (3.1%) were fibrosis‐free, and the others presented with Stage 1 ( n = 23; 35.4%), Stage 3 ( n = 23; 35.4%), Stage 4 ( n = 9; 13.8%), or Stage 5 ( n = 8; 12.3%) pulmonary fibrosis. Conclusion: This study demonstrates that colchicine therapy might reduce pulmonary fibrosis progression in individuals affected by COVID‐19 pneumonia. Clinicians should consider colchicine treatment to prevent pulmonary fibrosis.

29 July 2024 in Anatolian Current Medical Journal
Verified
Journal Article
Open access
PDF file
MBMustafa Ilteris Bardakçı
Mustafa Ilteris Bardakçı
GAGülhan Albayrak
Gülhan Albayrak
MÖMüfide Arzu Özkarafakılı
Müfide Arzu Özkarafakılı
RGRemzi Gediz
Remzi Gediz
Aims: Community-acquired pneumonia (CAP) is a term used to describe an acute lung infection that develops outside of a hospital setting. Radiological sequelae may remain in a certain part of these patients that may affect their lives. We aimed to investigate the frequency of sequelae parenchymal lesions and influencing factors in patients with community-acquired pneumonia. Methods: This retrospective study included patients diagnosed with CAP. First, patients who were admitted to the chest diseases outpatient clinic for any reason and who were treated with the diagnosis of CAP in the emergency department 12 months ago at the earliest were selected. Among these patients, patients with thorax computed tomography (chest-CT) under the control of the chest diseases outpatient clinic were included in the study. Chest-CT results, demographic data and laboratory data were evaluated. Results: A total of 80 patients, 32 (40%) female and 48 (60%) male, diagnosed with CAP were included. The mean age of our patients was 56.83±13.41 (min-max: 18-71). Twenty-three (28.75%) of the patients did not have pathology in the control chest-CT, while 57 (71.25%) patients had various levels of sequelae changes. Of the sequelae observed in 57 patients, 34 (42.5%) had single linear atelectasis or single band formation or ectasia in a single bronchus, while fibrotic structure was detected in 23 (28.75%). Five (6.25%) patients had pulmonary fibrosis. Age and smoking have a statistically significant effect on the presence of fibrosis in patients with CAP. Conclusion: Mild to severe fibrotic changes were observed in one-third of our patients one year after CAP treatment. In our study, fibrotic changes were found to be highly correlated with age and smoking.